A number of small molecule LIMK inhibitors have been discovered [6, 21–25] and several have been reported to be efficacious as single agent therapeutics on cancer cells including: breast [6, 26], pancreatic [27], prostate [5], cervical adenocarcinoma [6], fibromatosis [28], leukemia [4, 6] and glioma [29]. The gene discussed is LIMK1; the disease is cancer.